COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR ET TRAITER DES MALADIES HÉPATIQUES, CONTENANT, EN TANT QUE SUBSTANCE ACTIVE, DE LA CROMOLYNE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI
The present invention relates to a pharmaceutical composition for preventing and treating liver diseases, containing, as an active ingredient, cromolyn or a pharmaceutically acceptable salt thereof. Cromolyn inhibits the accumulation of collagen, which is known as a major secretion marker of hepatic stellate cells (HSCs), and the production of TGF-β, inhibits hepatocyte migration caused by the treatment of hepatocytes with TGF-β, inhibits an E-cadherin expression decrease caused by EMT progression, and has an anti-aging effect on hepatocytes, so as to have a dual effect of inhibiting the activity of HSCs and recovering the function of hepatocytes, thereby being usable as a fundamental therapeutic agent for various liver diseases including liver cirrhosis.La présente invention concerne une composition pharmaceutique pour prévenir et traiter des maladies hépatiques, contenant, en tant que substance active, de la cromolyne ou un sel pharmaceutiquement acceptable de celle-ci. La cromolyne inhibe l'accumulation de collagène, qui est connue comme étant un marqueur de sécrétion majeur des cellules stellaires hépatiques (CSH), et la production de TGF-β, inhibe la migration des hépatocytes causée par le traitement d'hépatocytes avec TGF-β, inhibe une diminution de l'expression de E-cadhérine causée par une progression de TEM, et a un effet antivieillissement sur les hépatocytes, de manière à avoir un double effet d'inhibition de l'activité de CSH et la récupération de la fonction des hépatocytes, de manière à être utilisable en tant qu'agent thérapeutique fondamental pour différentes maladies hépatiques comprenant la cirrhose du foie.본 발명은 크로몰린(cromolyn) 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 간질환 예방 및 치료용 약학적 조성물에 관한 것으로, 크로몰린은 간성상세포(Hepatic stellate cell, HSC)의 주요 분비 마커로 알려진 콜라겐 축척 및 TGF-β의 생성을 억제할 뿐만 아니라, 간세포에서 TGF-β 처리로 인한 간세포의 이동을 억제하고, EMT 진행으로 인한 E-카데린(E-cadherin)의 발현 감소를 억제하며, 간세포의 항노화 효과를 가지므로, HSC 세포의 활성을 억제하는 효과를 가질뿐만 아니라 간세포의 기능을 회복시키는 이중적인 효과를 가지므로, 간경변증을 포함하는 다양한 간 질환
